N/A N=4,132 Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming
Cardiovascular Disease
Primary: Change in Shock Reduction Programming Adoption — 13.6; 6.8; 9.0; 3.5 percentage of participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=142 Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
Shock · Cardiovascular Diseases · Critical Illness
Primary: Perfused Vessel Denisty (PVD) — 22.8; 23.8; 20.2; 22.5 mm/mm^2
N/A N=20 Cardiogenic Shock Intravascular Cooling Trial
Cardiogenic Shock
Primary: Number of Participants With Episodes of Arrhythmia — 0; 1 Participants — p=1
N/A N=44 Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
Circulatory Shock · Cardiovascular Shock
Primary: Perfused Vessel Density (PVD) — 24.81; 20.44; 26.41; 21.88 mm/mm^2
Phase 2 N=50 Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)
Hemorrhagic Shock
Primary: Survival — 16; 21 participants — p=.252
N/A N=72 Disrupt CAD IV With the Shockwave Coronary IVL System
Coronary Artery Disease · Myocardial Infarction
Primary: Percentage of Participants Who Experienced Freedom From MACE Within 30 Days Post-procedure — 93.8 percentage of participants
N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
Phase 2 N=101 AVERT Shock: Arginine Vasopressin During the Early Resuscitation of Traumatic Shock
Traumatic Shock
Primary: Number of Blood Products Transfused — 1.7; 3.0 Litre
N/A N=60 Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)
Peripheral Arterial Disease
Primary: Effectiveness Endpoint Defined as Number of Participants withTarget Lesion Patency by Duplex Ultrasound Defined as Freedom From ≥50% Restenosis — 30 Participants
N/A N=47 Synchronized Cardiac Assist for Cardiogenic Shock
Shock, Cardiogenic · High Risk Percutaneous Coronary Interventions
Primary: Number of Participants With Device and Procedure Related Serious Adverse Events — 11; 5 Participants
N/A N=145 Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)
Coronary Artery Disease · Myocardial Infarction
Primary: Percentage of Participants Who Experienced Freedom From Major Adverse Cardiac Events (MACE) Within 30 Days Post-procedure — 98.6 Percentage of participants
N/A N=84 Bundling and Unbundling the Laparoscopic Electrosurgery Cord With the Camera Cord
Fatigue
Primary: Histologic Thermal Injury to Umbilical Port Site Skin — 24; 13 participants
N/A N=24 Extracorporeal Shockwave Therapy for Diabetic Foot Wounds
Diabetic Foot · Wound
Primary: Wound Volume — 1.16 cm^3
Phase 4 N=24 Effect of Deep BLock on Intraoperative Surgical Conditions
Prostate Hypertrophy · Renal Disease
Primary: Surgical Rating Scale — 4; 4.7 units on a scale (1-5) — p=<0.001
N/A N=406 National Cardiogenic Shock Initiative
Cardiogenic Shock · Acute Myocardial Infarction · STEMI - ST Elevation Myocardial Infarction
Primary: Number of Participants Who Survived at Discharge — 287 Participants
Phase 4 N=128 The Laparotomy Study
Gastrointestinal Cancer
Primary: Surgical Rating Score — 4; 4.75 units on a scale — p=<0.05
Phase 2 N=50 Corticosteroid Therapy in Refractory Shock Following Cardiac Arrest
Cardiac Arrest
Primary: Time to Shock Reversal — 55; 49 hours
N/A N=94 The Use of a High-frequency Ultrasonic Knife in Breast Cancer Surgery
Breast Cancer
Primary: Drainage Volume — 182.6; 525.2 milliliters — p=<0.05
N/A N=1,051 Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)
Hemorrhagic Shock · Traumatic Brain Injury
Primary: 4 Hour Mortality — 50; 32 Participants
Phase 4 N=70 The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery
Neuromuscular Blockade
Primary: Number of Participants With Increased Intra-abdominal Pressure (IAP) Alarm as > 15 mmHg — 14; 6 Participants
N/A N=234 The SURGICEL® Powder Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding (China Study)
Hemorrhage
Primary: Hemostatic Success at 5 Minutes — 109; 103 Participants — p=<0.0001
N/A N=250 Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System
Peripheral Artery Disease
Primary: Number of Participants With Procedure Success — 232 Participants
N/A N=431 Disrupt CAD III With the Shockwave Coronary IVL System
Coronary Artery Disease · Myocardial Infarction
Primary: Number of Participants Who Experienced Freedom From Major Adverse Cardiac Events (MACE) Within 30 Days Post-procedure — 92.2 percentage of participants
N/A N=60 A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery
Colon Cancer
Primary: Overall Time for Dissection of the Soft Tissues — 91; 77 minutes — p=0.214
Phase 2 N=200 Cold Stored Platelet in Hemorrhagic Shock
Trauma · Hemorrhage
Primary: Study Feasibility — 91; 82 Participants
N/A N=35 Safety and Performance Study of the Shockwave Lithoplasty System
Peripheral Arterial Disease
Primary: Composite of New-onset Major Adverse Events (MAE) — 0 participants
N/A N=48 Acute Subcutaneous Defibrillation
Ventricular Arrhythmias
Primary: Subjects Will Demonstrate a Successful Defibrillation Outcome if They Have 2 Successful Defibrillation Shocks With the Research System. — 85.7 percentage of success
N/A N=26 Magnetic Stimulation to Treat VT Storm
Ventricular Tachycardia
Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants
N/A N=30 Cooling Vest May Reduce Heat Stress During Surgery
Body Temperature Changes
Primary: Self-rated Thermal Comfort. — 4.4; 6.6 score on a scale — p=<0.001
N/A N=42 Intraoperative Warming Comparison of Devices
Hypothermia
Primary: Percent of Patients With an Average Intraoperative Temperature Greater Than or Equal to 36 Celcius — 56; 90 percentage of participants — p=0.027